Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BRIEF-A Global Executive Composite score (GEC) ≥ 65, or Behavioral Regulation Index score (BRI) ≥ 65, or Metacognition Index score (MI) ≥ 65.~* Subjects must meet consensus criteria for chronic fatigue syndrome.~* Provide written informed consent for participation in the trial before completing any study-related procedures.~* 18-60 years at time of consent~* Male or non-pregnant females who are not breastfeeding.~* Females of reproductive potential must agree to use a medically accepted means of contraception when engaging in sexual intercourse at any time during the study.~* Are able to swallow study medication.~Exclusion Criteria:~* CFS and executive functioning impairment are not present or not diagnosable~* Serious comorbid psychiatric condition~* Subjects who were pregnant, nursing, or intended to become pregnant~* Subjects who had been on a psychostimulant regimen in the last six months~* Subjects who had a medical condition that would have been affected by psychostimulant medication~* Subjects who were of low intelligence, or who were unable to communicate effectively with the study team

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Lisdexamfetamine Dimesylate (Type: ACTIVE_COMPARATOR): Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
- Sugar pill (Type: PLACEBO_COMPARATOR): Matching Placebo 30, 50 or 70 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).